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ABSTRACT 
 
Juvenile idiopathic arthritis (JIA) is the commonest rheumatic disease in children and JIA-
associated uveitis its most frequent extra-articular manifestation.  The uveitis is potentially 
sight-threatening and so carries a considerable risk of morbidity with associated reduction in 
quality of life.   The commonest form of uveitis seen in association with JIA is chronic 
anterior uveitis which is almost always asymptomatic in the initial stages.  Therefore, 
screening for JIA-associated uveitis in at-risk patients is essential.  The aim of early detection 
and treatment is to minimise intra-ocular inflammation and avoid complications leading to 
visual loss, which can result from both disease activity and medications. The sight-
threatening complications of JIA-associated uveitis include cataracts, glaucoma, band 
keratopathy and macular oedema.  There is increasing evidence for the early introduction of 
systemic immunosuppressive therapies in order to reduce topical and systemic glucocorticoid 
use.  A recently-published randomised controlled trial of adalimumab in JIA-associated 
uveitis now provides convincing evidence for the use of this biologic in patients who fail to 
respond adequately to methotrexate.  Tocilizumab and abatacept are being investigated as 
alternatives in children inadequately treated by anti-tumour necrosis factor drugs.  
  
  
INTRODUCTION 
 
Uveitis is a condition characterised by inflammation of the uveal components of the eye, 
namely the iris, choroid and retina.(1, 2)  Classification has been defined in terms of the 
anatomy and time course of disease according to the Standardisation of Uveitis Nomenclature 
(SUN) international working group.(3, 4)  Anatomically it can be described as anterior, 
intermediate, posterior or panuveitis (Figure 1).  Uveitis onset may be sudden or insidious 
and its duration limited (≤ 3 months) or persistent (> 3 months).(3)  The temporal pattern is 
described as acute (sudden onset and limited duration), recurrent (repeated episodes separated 
by periods of inactivity without treatment ≥ 3 months in duration) or chronic (persistent 
uveitis with relapse in < 3 months after discontinuing treatment).  Uveitis can also be 
classified by aetiology into infectious and non-infectious.   
 
 
  
  
Figure 1: Cross-section of eye showing areas affected in anterior, intermediate and posterior 
uveitis and potential complications (in brackets). Permission obtained from Wiley © Hughes, 
E.H. & Dick, A.D. The pathology and pathogenesis of retinal vasculitis. Neuropathol. Appl. 
Neurobiol. 29, 325–340 (2003).(5) 
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In children with rheumatological disease, uveitis is seen associated with JIA, juvenile 
sarcoidosis / Blau syndrome and Behçet’s disease.(6)  The commonest form of uveitis is the 
chronic anterior type associated with juvenile idiopathic arthritis (JIA), and this will be the 
main focus of this review.  This form of uveitis, which is usually asymptomatic, is most 
frequently associated with oligoarticular and rheumatoid factor (RF) negative polyarticular 
categories of JIA.  Acute anterior uveitis, which often presents with a painful, red eye, can 
also occur in JIA, and is usually associated with enthesitis-related arthritis (ERA) and HLA-
B27 positivity.  If inadequately treated, JIA-associated uveitis (JIA-U) can lead to ocular 
complications, including glaucoma, cataracts, band keratopathy and persistent cystoid 
macular oedema, and can ultimately result in visual impairment and blindness.(7)  
Management of JIA-U involves use of both topical and systemic agents with clinical trials of 
biologic agents recently completed or underway.(8, 9) 
 
 
 
EPIDEMIOLOGY 
Children represent approximately 5-10% of all patients with uveitis (10).   The overall 
incidence of uveitis in the childhood population, reported in a study from Finland, was 4.3 
per 100,000/year and prevalence of 27.9 per 100,000 (11).  Among all causes of paediatric 
uveitis, when stratified by aetiology, the prevalence of JIA-U ranged from 15-67% across 
centres in Europe, North America and Israel (10, 12-15).  In a cohort of 642 children with 
uveitis in Tamil Nadu, India, infectious uveitis was most common representing 54.9%, 
followed by idiopathic and non-infectious at 32.5% and 12.6% respectively (16).  It should be 
noted that uveitis can precede a diagnosis of arthritis in 3-7% of children with JIA (17) and 
thus children presenting with uveitis need careful assessment for underlying systemic or 
infectious disease.  
 
  
How common is uveitis associated with JIA? 
In patients already known to have JIA, estimates of prevalence of uveitis range from 11.6% 
(18) to 30% (19) although overall it appears to be decreasing over the past decade.  A 
longitudinal cohort study conducted in Nordic countries prospectively followed 435 children 
diagnosed with JIA in 1997-2000 for a median of 96 months (20).  Uveitis developed in 89 
(20.5%) children.  No patients with systemic or RF-positive JIA developed uveitis.  The 
frequencies of chronic uveitis in other categories were: 35.7% in juvenile psoriatic arthritis, 
22.5% in RF-negative polyarticular, 20.5% in extended oligoarticular, 19.1% in persistent 
oligoarticular, 19.0% in undifferentiated and 8.3% in ERA.  Regarding disease pattern, the 
majority (80 children) had chronic uveitis while the remaining 9 patients had acute uveitis, all 
but one of whom had ERA.  In another study where 13.1% of 1081 JIA patients developed 
uveitis, chronic anterior uveitis was also predominant (68.3%) (21).  However, acute anterior 
disease (16.2%), recurrent anterior disease (12%) and panuveitis (3.5%) were also 
encountered. 
 
What are the risk factors for development of uveitis in JIA? 
Several risk factors for JIA-U have been identified.  These include age of onset, gender, JIA 
category, and ANA and HLA-B27 positivity (7, 17, 19, 22, 23). A younger age, female 
gender, oligoarticular disease and presence of ANA are risk factors for chronic anterior 
uveitis.  In contrast, being male with ERA and HLA-B27 predispose to acute anterior uveitis.   
The interaction between individual risk factors is likely to be inter-dependent and 
complex.  In a retrospective study of 1047 patients with JIA, the risk of developing uveitis 
was age-dependent in girls, but not boys (24).  This finding seems to have been confirmed by 
the Nordic longitudinal study in which the median age at onset of arthritis in girls with uveitis 
was 3.4 years versus 6.8 years in girls without uveitis (p<0.001) (20).  The difference in age 
  
at onset in boys was not significant (p=0.39).  The study also identified anti-histone 
antibodies (AHA) ≥ 15 U/mL as a significant predictor of uveitis, but only in girls and not 
boys. 
The impact of ethnicity on JIA-U is unclear.  Early studies identified JIA-U in many 
different ethnic groups and suggested ethnicity did not play a role (25). More recent studies 
have suggested that those of European descent are at increased risk of JIA-associated uveitis 
compared to the at-risk local population (26). 
 
When do children with JIA develop uveitis? 
As discussed above, uveitis may precede arthritis in 3-7% of children with JIA.  In the Nordic 
study, uveitis develops at a median interval of 0.8 (range -4.7 to 9.4) years after onset of 
arthritis.  A single centre study conducted in Atlanta, USA, which included 52 children with 
JIA-U found that 24% were diagnosed with uveitis prior to arthritis, 22% within the first year 
after onset of arthritis and cumulatively 86% within 4 years of JIA diagnosis (23).   
Sabri et al found that the mean time from onset of JIA to onset of uveitis was 1.8 
years (21).    Additionally, a recent study has suggested a biphasic course for the condition 
with a second peak of disease activity occurring around puberty (27) suggesting the need for 
vigilance in monitoring these patients over time. 
 
 
PATHOGENESIS 
The cause of the intraocular inflammation is not fully understood despite the strong 
association between JIA and uveitis being recognised for many years. There have been 
infrequent reports of familial cases of JIA-U.(28)  However monogenic or Mendelian patterns 
of inheritance of JIA-U have not been seen (29), suggesting more complex genetic 
pathogenesis.  
  
Uveitis in oligoarticular JIA has been linked with the HLA-DR5 haplotype and HLA-
DRB*1104 allele; the combination of HLA-DRB1*1104 and HLA-DPB1*0201 is associated 
with a 7.7-fold increased risk of chronic uveitis (30, 31). The HLA-DR1 haplotype and HLA-
DQA*0101 allele, in contrast, are protective.  HLA-B27, which is seen more frequently in 
ERA, confers an increased risk of acute anterior uveitis (32). The associations with HLA type 
support the theory that JIA-U is an autoimmune disorder.   It is thought that an immune 
response is triggered against intraocular antigens including S-arrestin (also known as retinal 
S-antigen), retinol-binding protein 3 (RBP3), and tyrosinase-related proteins (33).  
Both B- and T-lymphocytes appear to be involved in pathogenesis of non-infectious 
uveitis.  Immunohistochemistry of eye biopsies from patients with JIA-U showed a 
predominance of CD4+ T cells compared with CD8+ T cells and variable levels of CD20+ B 
cells.(34)   CD4+ T cells of T helper type 1 (TH1) and TH17 subsets produce IFN-γ and IL-17, 
respectively (35-37). The pro-inflammatory effects of these cells are counterbalanced by 
CD4+ CD25+ FoxP3+ T regulatory (TREG) cells and inducible TREG cells. Although there is 
evidence for a role of TH1, TH17 and TREG cells in uveitis pathogenesis, the exact roles of the 
T cell subsets in the course of disease has not been fully defined (34, 38, 39).  
As noted previously, ANA positivity is a risk factor for JIA-U which raises the 
question of whether auto-antibodies are involved in the pathogenesis (40).  Although a 
correlation between ANA and plasma cell infiltration in anterior uveitis has been reported, 
the specific intraocular antigens and whether ANAs are actually pathogenic are not clear (34). 
Potential targets of autoantibodies have been studied using immunofluorescence of tissue 
sections from eyes incubated with sera from patients with JIA (41).  When using patient sera 
compared with controls, there appeared to be an increased frequency of antibodies against the 
iris and retina, but not the ciliary body. However, because blood samples were taken after 
uveitis was well established, it is not clear whether the anti-ocular antibodies are part of the 
  
cause or consequence of disease. In future, serial serum samples taken from JIA patients 
before and after onset of uveitis could enable the potential prognostic significance of 
antibody binding to be investigated. 
Macrophages, in addition to lymphocytes, are seen in biopsy samples of eyes with 
uveitis (34).  Both cell types exert pro-inflammatory effects through secretion of cytokines 
and chemokines. In one study including children with JIA-U, levels of IL-2, IL-6, IL-13, IL-
18, IFN-γ, TNF, soluble ICAM-1 (also known as CD54), CCL5 and CXCL10 in the aqueous 
humour were considerably higher than in controls without uveitis (42). 
 
 
CLINICAL FEATURES 
How does JIA-associated uveitis present? 
 
In the case of  acute anterior uveitis, presentation can be with overt symptoms (1).  Typical 
features include photophobia, eye pain, redness, visual changes and headaches.  However, 
chronic anterior uveitis, more commonly seen in JIA, is often completely asymptomatic.  
Therefore, regular screening for uveitis in patients with JIA is essential to detect clinically-
silent, but potentially vision-threatening, disease.  Younger children, in particular, may be 
unable to report reliably any visual changes, so the need for formal assessment of vision and 
the education of families of the importance of this is vital. 
 
It is well-recognised that uveitis can develop before the onset of arthritis, and in these 
cases the eye inflammation may go unnoticed for a significant period (17, 20, 23).  In all 
children diagnosed with non-infectious uveitis, features of systemic disease, including JIA, 
should be actively sought at the time of diagnosis and the potential of an underlying condition 
revisited over subsequent months.    
  
 
DIAGNOSIS AND SCREENING 
Which patients should undergo screening for uveitis? 
All patients at risk of JIA-U should be screened for uveitis.  Screening guidelines are 
available in several countries including the UK (43), Germany (44) and USA (45, 46).  The 
UK guidelines are summarised in Box 1.  Consensus standards in the UK recommend first 
ophthalmological assessment to take place within 6 weeks of JIA being diagnosed or 
suspected (47), underlining the importance of  prompt diagnosis and treatment.  Systemic 
immunosuppression used to treat arthritis may be controlling uveitis even in patients with no 
previous intra-ocular inflammation.  Therefore, UK guidelines recommend increasing 
frequency of screening to 2-monthly for the first 6 months after stopping methotrexate or 
other systemic treatment (43). 
  
  
 
Box 1: British Society for Paediatric and Adolescent Rheumatology/ Royal College of 
Ophthalmology guidelines for uveitis screening in JIA (43). 
 
Referral 
• Patients should be referred at time of diagnosis, or suspicion, of JIA 
 
Initial screening examination 
• Should occur as soon as possible and no later than six weeks from referral 
• Symptomatic patients should be seen within a week of referral 
 
Ongoing screening 
• Screening at two monthly intervals from onset of arthritis for six months 
• Followed by 3-4 monthly screening for time outlined below: 
o Oligoarticular JIA, psoriatic arthritis and enthesitis related arthritis 
irrespective of ANA status onset under 11 years 
Age at onset Length of screening 
< 3 years 8 years 
3-4 years 6 years 
5-8 years 3 years 
9-10 years 1 year 
 
 
 
 
 
 
 
o Polyarticular, ANA +ve JIA, onset <10 years 
Age at onset Length of screening 
< 6 years 5 years 
6-9 years 2 years 
 
 
 
 
 
o Polyarticular, ANA –ve JIA, onset <7 years 
Five year screening for all children 
 
o Systemic JIA and rheumatoid factor +ve polyarticular JIA 
Uveitis risk very low, however diagnostic uncertainty in the early stages and 
overlap of symptoms may mean initial screening is indicated 
 
o All categories, onset >11years 
One year screening for all children 
 
o After stopping immunosuppression eg methotrexate 
Two monthly screening for six months, then revert to previous screening 
frequency as above 
 
o After discharge from screening 
Patients should receive advice about regular self-monitoring by checking 
vision uniocularly once weekly and when to seek medical advice  
Screening may need to continue indefinitely in situations where young 
person may be unable to detect a change in vision or be unwilling to seek 
re-referral 
Annual check by optometrist as a useful adjunct 
 
  
How is JIA-associated uveitis diagnosed and monitored? 
Screening of children with JIA for uveitis involves a combination of age-appropriate visual 
acuity (VA) testing, measurement of intraocular pressure and slit lamp examination.  The 
latter allows examination of the anterior and posterior chambers as well as the retina.  A 
diagnosis of uveitis is made based on features of inflammation on slit lamp examination 
which include cells in the anterior chamber (AC) (1) and AC flare resulting from protein 
leakage into the AC due to breakdown of the blood–aqueous humour barrier (48).  Intra-
ocular inflammation is graded according to the SUN criteria which take into account AC 
cells, AC flare, vitreous cells, and vitreous haze or debris (Box 2).  The criteria also provide 
definitions of improvement and worsening of the condition (Box 2) allowing reproducible 
assessment and monitoring of uveitis activity.  It is important to note that 0.5+ AC cells 
should not be considered inactive uveitis (3). 
  
  
Grading scheme for anterior chamber cells 
 
Grade Cells in field* 
0 <1 
0.5+ 1-5 
1+ 6-15 
2+ 16-25 
3+ 26-50 
4+ >50 
 
Grading scheme for anterior chamber flare 
 
Grade Description 
0 None 
1+ Faint 
2+ Moderate (iris and lens details clear) 
3+ Marked (iris and lens details hazy) 
4+ Intense (fibrin or plastic aqueous) 
 
Activity of uveitis terminology 
 
Term Definition 
Inactive Grade 0 cells† 
Worsening activity Two step increase in level of inflammation 
(e.g. anterior chamber cells, vitreous haze) 
or increase from grade 3+ to grade 4+ 
Improved activity Two step decrease in level of inflammation 
(e.g. anterior chamber cells, vitreous haze) 
or decrease to grade 0 
Remission Inactive disease for >3 months after 
discontinuing all treatments for eye disease 
 
*Field size is 1mm by 1mm slit beam 
†Applies to anterior chamber inflammation 
 
 
Box 2: Standardisation of Uveitis Nomenclature (SUN) criteria for uveitis activity 
[adapted with permission from Elsevier © Jabs et al. Am J Ophthalmol 140, 509-16 
(2005)(3)] 
 
Both inflammation and topical glucocorticoids used as treatment increase the risk of 
intraocular hypertension and glaucoma.  Therefore, regular measurement of intraocular 
  
pressure is important in patients with JIA-U.  The risk remains, despite control of active 
inflammation, as illustrated by one study showing the first measurement of raised intraocular 
pressure at a time when the disease was inactive in 60% of eyes (49).   
 
The assessment of VA provides a measure of both disease activity and visual damage 
resulting from both chronic disease activity and failure or complications of treatment.(2)  
Guidelines for measuring outcome in JIA-U, which include assessment of VA as a key 
component, have been developed (50).  This should be best corrected visual acuity (BCVA) 
using age-appropriate tests recorded monocularly and binocularly and converted to logMAR.  
Several complications of JIA-U can contribute to visual loss.  These include glaucoma, 
hypotony, cataract, band keratopathy, posterior synechiae, macular oedema, epiretinal 
membrane, and optic disc oedema.   
 
TREATMENTS 
Early detection, through rapid referral and regular screening, and appropriate assessment of 
disease activity are key to the management of JIA-U.  This relies on effective communication 
between paediatric rheumatologists and ophthalmologists which may be helped by 
organisation of multi-disciplinary clinics.  The target of effective treatment is to achieve 0 
cells in the anterior chamber (SUN AC cell grade 0) in both eyes (51).  Practical management 
protocols have recently been published both by our group in Bristol, UK (52) and an 
interdisciplinary panel from Spain (51).  Figure 1 shows a modified algorithm based on 
consensus guidelines for management of chronic anterior uveitis (51-53). 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Active Uveitis 
(AC cell grade > 0.5+) 
Adverse prognostic factors 
(Poor VA, hypotony, glaucoma, 
cataract, macular oedema, dense 
opacities of vitreous) 
Topical 
corticosteroids (every 
1-2h for 1-3d then 
wean) + Cycloplegic 
Improvement of 2 grades but 
not ≤ 0.5+ 
Continue tx for 3w and reassess 
 
No improvement of 2 grades or 
worsening or ≥ 3 flares or flares 
with sequelae 
MTX 15mg/m
2
 weekly po or sc 
 
Topical corticosteroids 
(every 1-2h for 1-3d 
then wean) + 
Cycloplegic + Systemic 
corticosteroids 
 
YES NO 
Improvement and 
grade 0 
No further action  
Improvement of 2 grades but 
not ≤ 0.5+ 
Continue tx for 6w and reassess 
 
No improvement of 2 grades or 
worsening or ≥ 3 flares or flares 
with sequelae 
MTX 15mg/m
2
 weekly po or sc 
+ Adalimumab* 
 
Improvement and 
grade 0 
Maintenance 
MTX for 12m or 
24m if poor 
visual prognosis  
Improvement of 2 grades but 
not ≤ 0.5+ 
Try to achieve inactivity with ≤ 
2 drops/day topical steroids 
 
No improvement of 2 grades or 
worsening or ≥ 3 flares or flares 
with sequelae 
Maximise drug dosage; Optimise 
treatment interval and route; 
Check compliance; Measure drug 
levels and ADAbs (if possible) 
Consider oral steroid ± subtenons 
if grade 3+ or 4+ 
 
 
Improvement and 
grade 0 
Maintenance tx 
for 24m  
Improvement of 2 grades but 
not ≤ 0.5+ 
Try to achieve inactivity with ≤ 
2 drops/day topical steroids 
 
No improvement of 2 grades or 
worsening or ≥ 3 flares or flares 
with sequelae 
Switch Adalimumab to 
Infliximab, Tocilizumab or 
Abatacept* 
 
Improvement and 
grade 0 
Maintenance tx 
for 24m  
3 months 
3 weeks 
3 months 
3 months 
  
 
 Figure 1: Treatment algorithm for juvenile idiopathic arthritis-associated uveitis   
[Adapted with permission from Springer © Bou, R. et al. Rheumatol Int 35, 777-785 (2015) 
[36] and from Springer © Heiligenhaus, A. et al. Rheumatol Int 32, 1121-1133 (2012) [38] ] 
 
At all stages aim to minimise topical steroid to ≤ 2 drops/day while maintaining AC cell 
grade ≤ 0.5+ 
* Mycophenolate mofetil (MMF) is a potential alternative to a biologic drug if there is active 
uveitis but no active arthritis 
Legend: AC: anterior chamber, d: days, h: hours, m: months, MTX: methotrexate, po: by 
mouth, sc: subcutaneous, tx: treatment, VA: visual acuity, w: weeks  
 
 
Guidelines on management of JIA-U advise that therapy is initiated when the AC cell 
grade is > 0.5+  (53).  Treatment is also indicated when there is fibrin in the AC and 
keratocytic precipitates with corneal oedema and loss of VA.  Failure to see improvement in 
inflammation or presence of poor prognostic factors are indications for intensification of 
immunosuppressive treatment.  Poor prognostic factors are: impaired initial vision, cataract, 
glaucoma, ocular hypotony, dense vitreous body opacification and macular oedema.  Band 
keratopathy, synechiae, cataract and glaucoma alone, in the absence of active uveitis, do not 
require anti-inflammatory treatment (53). 
 
What are the first- and second-line treatments for JIA-associated uveitis? 
The first-line treatment for both acute and chronic anterior uveitis is topical glucocorticoids 
(53-55).  The primary indication for systemic immunosuppression with one of the DMARDs 
is failure of adequate control of inflammation after 3 months of topical treatment, particularly 
with > 3 drops daily (53).    Methotrexate (MTX) remains the first second-line therapy after 
topical glucocorticoids.  The use of, and evidence for, local and systemic glucocorticoids, 
cycloplegics and non-biologic DMARDs have been reviewed by us recently (1, 2) and so are 
not discussed in detail here.  Table 1 summarises the range of non-biological 
immunosuppressants used to treat JIA-U, their doses and evidence base.  Current treatment 
  
algorithms recommend that if there is worsening disease or failure to achieve AC cell grade 0 
after 3-4 months on MTX, then a biologic drug is added (51, 56) 
 
  
  
Table 1: Non-biological immunosuppressants used in treatment of JIA-associated 
uveitis 
 
Drug name Mechanism Dosage and 
route 
Common side 
effects 
Evidence Key 
references 
Methotrexate Cellular 
adenosine 
release(57) 
10-15mg/m2 
po or sc once 
weekly 
GI discomfort, 
nausea, elevated 
liver enzymes 
Systematic review and 
meta-analysis of 
retrospective case 
series (n=135): 
improvement in 73% 
(58) 
Azathioprine Purine 
nucleoside 
analogue, 
inhibits DNA 
replication 
1mg/kg od, 
increasing to 
maximum 
3mg/kg od 
GI discomfort, 
bone marrow 
suppression, liver 
impairment 
Retrospective case 
series (n=41): uveitis 
inactivity in 61.5% as 
initial monotherapy; 
66.7% as combination 
therapy 
(59) 
Mycophenolate 
mofetil 
Inhibitor of 
inosine-5-
monophosphate 
dehydrogenase 
300mg/m2 bd, 
increasing to 
600mg/m2 bd 
GI discomfort, 
leukopenia, hair 
loss 
Several retrospective 
case series (n=17, 52 
and 85; not all with 
JIA, variable outcome 
measures): response in 
55-88% 
(60-62)  
Ciclosporin Calcineurin 
inhibitor 
blocking T cell 
proliferation 
2.5-
5mg/kg/day in 
2 doses 
GI disturbance, 
hypertension, 
renal and liver 
dysfunction, lipid 
abnormalities 
Retrospective case 
series (n=82 and 14): 
uveitis inactivity in 
24% as monotherapy, 
48.6% as combination 
therapy 
(63, 64)  
Tacrolimus Calcineurin 
inhibitor 
blocking T cell 
proliferation 
50-150 
microgram/kg 
bd 
GI disturbance, 
hypertension, 
renal and liver 
dysfunction, lipid 
abnormalities, 
blood disorders 
Retrospective case 
series (n=62, mostly 
adults with idiopathic 
uveitis): permitted 
glucocorticoid 
tapering and improved 
visual acuity 
(65)  
 
Legend: bd- twice daily; GI- gastro-intestinal; od- once daily; po-  by mouth; sc- 
subcutaneous. 
  
  
Which biologic drugs are effective in JIA-associated uveitis? 
Over the past decade, randomised controlled trials (RCTs) of biologic agents have 
demonstrated their efficacy in controlling joint disease in JIA (66).  The same drugs have also 
been used in treatment of associated uveitis (Table 2).  
Table 2: Biological immunosuppressants used in treatment of JIA-associated uveitis 
 
Target Drug 
name 
Drug class Dosage and 
route 
Evidence Key 
references 
 
 
 
 
 
 
TNFα 
Etanercept Dimeric 
fusion 
protein 
Not recommended 
for treatment of 
JIA-U 
RCT: no more effective than 
placebo. Case reports of new 
uveitis on etanercept 
(67, 68)  
Infliximab Chimeric 
(mouse-
human) 
mAb 
6mg/kg IV initially, 
then 3-10mg/kg. 2nd 
dose at 2 weeks, 
then every 4-8 
weeks depending 
on response 
Several case series showing 
efficacy 
(67) 
Adalimumab Fully human 
mAb 
24mg/m2 sc q2w 
In practice, often 
20mg sc q2w (body 
weight <30kg), 
40mg sc q2w (body 
weight ≥30kg) 
Several case series showing 
efficacy. RCT demonstrated 
greater efficacy of 
adalimumab vs placebo. 
(8, 67, 69) 
Golimumab Fully human 
mAb 
50mg sc q4w Case series (n=3) showing 
efficacy 
(70) 
IL-6 Tocilizumab Humanised 
mAb 
10mg/kg (body 
weight <30kg), 
8mg/kg (body 
weight >30kg) IV 
q4w 
Several case series showing 
efficacy. Phase II trial in 
progress 
(9, 71-75)  
CD80/86 
(CTLA4) 
Abatacept Fully human 
fusion 
protein 
10mg/kg IV at 
weeks 0, 2, 4 then 
q4w 
Case series (n=7 and n=2) 
showing efficacy. Lack of 
sustained response in severe 
uveitis (n=21) 
(76-80) 
CD20 Rituximab Chimeric 
(mouse-
human) 
mAb 
375mg/m2 or 
750mg/m2 IV, two 
doses 2 weeks apart 
Case series (n=10 and n=8 
with long-term follow-up) 
showing efficacy in most 
patients 
(81-83) 
 
Legend: CTLA-4- cytotoxic T-lymphocyte-associated antigen 4; IL- interleukin; IV- 
intravenous; JIA-U- juvenile idiopathic arthritis-associated uveitis; mAb- monoclonal 
antibody; od- once daily; ow- once per week; q2w- every 2 weeks; q4w- every 4 weeks; 
RCT- randomised controlled trial; sc- subcutaneous; TNF- tumour necrosis factor. 
  
  
Adalimumab 
The greatest evidence, previously derived from cohort studies (67) and recently from 
an RCT, supports the use of adalimumab in treatment of JIA-U.  A multi-centre, double-
blind, RCT of adalimumab versus placebo was designed to assess the efficacy and safety of 
the drug used to treat active JIA-U in children and adolescents aged 2 years and older (8).  
All recruited patients had active uveitis despite glucocorticoid and MTX therapy for at least 
12 weeks and continued on a stable dose of oral or subcutaneous MTX throughout the study.  
Eligible patients were randomised in a 2:1 ratio to receive adalimumab (20 mg in those 
weighing < 30 kg or 40 mg in those ≥ 30 kg) or placebo subcutaneously every 2 weeks.  The 
primary end point was the time to treatment failure (assessed by a multicomponent 
intraocular inflammation score).  Secondary end points included use of topical and systemic 
steroids, flare of uveitis, flare of JIA, Juvenile Arthritis Disease Activity Score (JADAS), 
minimal disease activity, the American College of Rheumatology (ACR) paediatric core 
outcome set variables and health-related quality of life.  All adverse events (AEs) were 
reported regardless of severity or perceived association with the trial intervention.  Patients 
were reviewed at 4, 8 and 12 weeks and then every 12 weeks until 18 months or until 
treatment failure, after which they continued to be seen for another 6 months.  The targeted 
recruitment was 114 patients to achieve 80% power.  However, the study was stopped early 
at the recommendation of the data and safety monitoring committee after randomising 90 
patients (60 to adalimumab and 30 to placebo) when a pre-specified stopping boundary (p < 
0.0001) was reached for the primary end point.  The time to treatment failure was 
significantly delayed by addition of adalimumab to MTX versus placebo (hazard ratio of 
0.25; 95% CI 0.12-0.40; p < 0.0001).  Treatment failure occurred in 27% of patients in the 
adalimumab group versus 60% in the placebo group.  A significantly greater proportion of 
patients on adalimumab were able to reduce topical steroids.  In post hoc analysis, 57% in the 
  
adalimumab group and 17% in the placebo group were classified as having a response.  There 
was no significant difference between the groups regarding health-related quality of life.  A 
total of 588 AEs were noted in 88% of patients on adalimumab and 83% on placebo, with 
minor infections and respiratory disorders being the most common.  Serious adverse events 
(SAEs) were more common in the adalimumab group (0.29/patient-year (PY) versus 
0.19/PY) as were AEs (10.07/PY versus 6.51/PY). 
Based on the above RCT, adalimumab is now the biologic drug with the strongest 
level of evidence of efficacy for treatment of JIA-U when added to MTX.  However, there 
remain a group of patients whose uveitis does not respond to adalimumab or who flare 
despite achieving initial control.  In one retrospective study, 59 of 68 patients who were 
treated with adalimumab achieved response within 6 months (84).  However, 8 of the initial 
responders subsequently discontinued the treatment because of reactivation of uveitis. 
 
Other anti-TNF agents 
A double-blind RCT of etanercept in 12 patients with JIA-U showed no difference 
between the drug and placebo (68).  The study, with this small number of patients, was 
powered to detect a difference only if greater than 70 percentage points between treatment 
arms.  Several studies have reported new onset of uveitis or flares while on etanercept (85-
87).  Although there is not clear evidence that etanercept causes uveitis, and it may occur 
while on other drugs, data from national registries show that etanercept is associated with a 
greater number of uveitis cases than adalimumab or infliximab (88).  Etanercept is not 
recommended in patients with JIA-U.     
  
A meta-analysis including 229 children with JIA-U has shown that adalimumab and 
infliximab have similar efficacy and both are superior to etanercept (67).  However, during 40 
months’ follow-up, uveitis more commonly remained in remission in those treated with 
adalimumab compared with infliximab (60% vs 18.8% respectively) (89).  A small case 
series has reported that switching between anti-TNF agents, particularly from infliximab to 
adalimumab, can regain control of uveitis (90). 
 
Tocilizumab 
Use of tocilizumab, a fully humanised anti-IL6R antibody, for treatment of JIA-U was 
previously reported only in small case series (71, 72).  Within the last two years, two larger, 
multi-centre, retrospective cohort studies including 17 and 25 patients respectively have been 
published (74, 75).  
Tappeiner et al. reported experience treating 17 patients (14 female; mean age 15.3 
years, range 7-30 years) with severe and refractory active JIA-U with tocilizumab (74).  All 
had previously failed glucocorticoids, non-biologic DMARDs and at least one anti-TNF.  The 
median time between onset of uveitis and starting tocilizumab was 10 years (range 3.9-27 
years). Thirteen (76.4%) had secondary ophthalmic complications at baseline.  Intravenous 
tocilizumab (8 mg/kg body weight) was administered at 4-weekly intervals. Uveitis activity 
using SUN classification, BCVA, optical coherence tomography (OCT), intraocular 
complications and arthritis activity were recorded at baseline and 3, 6, 9 and 12 months.  In 
patients with bilateral uveitis, results for the eye with the higher AC cell grade were reported.  
Any changes in treatment were at the discretion of the managing physician.   
  
Uveitis inactivity (AC cell grade = 0) was achieved in 4/17 (23.5%) at 3 months, 5/14 
(35.7%) at 6 months, 5/9 (55.6%) at 9 months and 4/8 (50.0%) at 12 months.  Ten patients 
showed inactivity for at least one visit but 7 patients had no response showed persisting 
activity throughout follow-up and 5 stopped treatment because of lack of efficacy. Cystoid 
macular oedema was present in 5 eyes at baseline and resolved in all with tocilizumab. 
Sparing of systemic corticosteroids or other immunosuppressive medications was possible in 
13 patients, however in 6 of these uveitis subsequently recurred (n = 3) or worsened (n = 3).  
There was no significant change in BCVA between baseline and the end of follow-up but 4 
patients developed new ocular complications.  No SAEs requiring discontinuation of 
tocilizumab were reported. 
As the authors point out, although tocilizumab seemed effective in some patients, it 
was a cohort with severe, refractory uveitis, many with long-standing, irreversible ocular 
damage.  Use of tocilizumab much earlier in the disease course, after failure of the first anti-
TNF or as the first biological DMARD, may show a higher response rate. 
Calvo-Río et al. reported their experience with tocilizumab treating 25 patients (21 
female; mean age 18.5 years, range 8-38 years; 47 affected eyes) with JIA-U refractory to 
glucocorticoids, non-biologic DMARDs and at least one biologic, in all cases including an 
anti-TNF.  The median time between onset of uveitis and starting tocilizumab was 8.8 years 
(interquartile range [IQR] 2.0-16.5 years).  Over half had complications at baseline including: 
cataracts (n = 13), glaucoma (n = 7), synechiae (n = 10), band keratopathy (n = 12), 
maculopathy (n = 9) and amblyopia (n = 5).  Intravenous tocilizumab (8 mg/kg body weight) 
was administered at 4-weekly intervals in 21 patients, 2-weekly in two, 8-weekly in one and 
2.9 mg/kg subcutaneously every week in one.  Uveitis activity, using SUN classification, 
macular thickness using OCT, BCVA and corticosteroid-sparing effect were the outcome 
  
measures recorded at baseline, 1 week and 1, 3, 6, and 12 months.  For AC cells and vitreous 
haze, each patient was considered as an independent variable.  Regarding BCVA and OCT 
differences, results were reported considering the number of affected eyes. 
Improvement in uveitis activity (AC cell grade according to SUN definition) was 
achieved in 16% at 1 week, 40% at 2 weeks, 64% at 1 month, 68% at 3 months, 79.2% 
(19/24) at 6 months and 88.2% (15/17) at 12 months.  Ocular remission was achieved in 19 
(76%) of the patients with median follow-up of 12 months (IQR 6-24 months).  Cystoid 
macular oedema improved in all 9 patients with this finding at baseline with significant 
reduction in macular thickness at 6 and 12 months.  Significant decreases in daily median 
dose of prednisolone from 10 mg at baseline to 2.5 mg at 6 months and 0 mg at 1 year were 
reported.  A statistically significant improvement in BCVA was observed from Snellen chart 
score 11.2 ± 7.0 / 20 at baseline to 12.8 ± 6/4 / 20 at 6 months.  Tocilizumab was withdrawn 
because of AEs in two patients: severe autoimmune thrombocytopenia in one patient, and 
autoimmune anaemia and thrombocytopenia in another.  A third patient had viral 
conjunctivitis and bullous impetigo which required temporary cessation of tocilizumab.  One 
patient stopped treatment because lack of efficacy. 
Overall, this study seems to report more favourable response to tocilizumab than that 
of Tappeiner et al. although there are some differences between the studies in whether certain 
outcomes were reported as per patient or per eye, and in the frequency/route of administration 
in a small number of patients.  The median time between uveitis onset and starting 
tocilizumab was slightly shorter in the study of Calvo-Río et al. at 8.8 years versus 10 years 
but the proportion of patients with specific ocular complications at baseline was similar in the 
two studies. 
  
Subcutaneous tocilizumab has been tested in clinical trials in adults with rheumatoid 
arthritis and shown to have comparable efficacy to intravenous administration with the 
benefit of self-administration and avoidance of more frequent hospital attendance (91).  
Clinical trials of subcutaneous tocilizumab in JIA are in long-term follow-up (92).  A case 
series of 4 patients with JIA and uveitis, who switched from the intravenous route when their 
disease was in remission to subcutaneous treatment, reported that all patients experienced 
relapse within a few months of switching (93).  Three patients suffered an ocular flare and 
two a joint flare; all stopped subcutaneous tocilizumab due to lack of efficacy. 
Further study of the role of tocilizumab in treatment of JIA-U is required and the 
APTITUDE trial, an open-label study of subcutaneous tocilizumab for anti-TNF-refractory 
JIA-U is currently recruiting patients in the UK (9). 
   
Other biologic drugs 
Experience using abatacept and rituximab for treatment of JIA-U has been reported in 
case series (Table 2).  Efficacy was seen in most patients although only small numbers have 
been reported.   
 
When should treatment for uveitis be stopped? 
The duration of maintenance therapy on biologic agents once uveitis is in remission is 
not clear.  Consensus recommendations suggest continuing treatment for 24 months of 
inactive disease (51).  One retrospective cohort study (n=50, 44% with JIA) has reported on 
uveitis reactivation after stopping infliximab (n=45) or adalimumab (n=5) (94). Of 19 
  
patients who achieved remission and were subsequently withdrawn from anti-TNFs, 63.8% 
had reactivation within 12 months and there did not appear to be an association with duration 
of medication-induced remission.  Another retrospective cohort study, which followed 
children with non-infectious uveitis after stopping systemic therapy, identified a higher 
probability of remining in remission in those with idiopathic rather than JIA-associated 
uveitis, if inactivity was achieved within the first 6 months of systemic therapy and if it was 
achieved by an anti-TNF treatment (95). 
 
Do biologic drugs cause uveitis? 
More data are increasingly available on the safety of biologic drugs in JIA and rates 
of adverse events such as uveitis.  Several studies have reported flares or new-onset uveitis 
while on etanercept (85-87).  Evidence from national registries suggests that etanercept is 
associated with a greater number of uveitis cases than adalimumab or infliximab (88).  
However, no definite causative effect of etanercept can be proved from these retrospective 
observational studies and the prescribing pattern of the different anti-TNFs may be a 
confounding factor (96).  A German registry study (n=3467 patients) suggested that in those 
patients with a known negative past history of uveitis the rate of a new uveitis event was 
3.2/1000 patient years (PY) in the MTX group, 1.9/1000PY in the etanercept monotherapy 
group and 0.9/1000PY in the group on the combination of both (97).  An observational study 
reporting adverse events in JIA patients receiving biologics in Finland (n=348 patients) 
reported a rate of new-onset uveitis of 0.8/100PY, 0.3/100PY and 0.5/100PY while on 
etanercept, infliximab and adalimumab respectively (98).  The rates of uveitis flare were 
2.8/100PY, 8.0/100PY and 3.8/100PY for each respective treatment.  The authors suggest 
that the apparently higher rate of flare while on infliximab is because most patients with a 
  
pre-existing diagnosis of uveitis were started on this drug during the observation period 
(1999-2009). 
 
 
PROGNOSIS 
Complications in JIA-U result both from the disease itself and its treatments.  The 
condition remains a cause of blindness in children and visual loss may be present at first 
assessment with one study describing VA of 20/50 or worse in 40.3% and 20/200 or worse in 
24.2% at presentation (99).  A systematic literature review looking at outcomes in JIA-U 
showed an adverse visual outcome (VA < 20/40 both eyes together) in 9.2% of those with 
uveitis (7).  The main complications were cataracts, glaucoma and band keratopathy 
occurring in 20.5%, 18.9% and 15.7% respectively.   
 
 One study focussing on long-term follow-up reported a cohort of 55 JIA-U patients 
diagnosed and treated between 1973 and 1982 (100).  Seven years after uveitis onset, 42% 
had cataracts and 5% glaucoma.  At 24 years, 51% had cataracts, 22% glaucoma and 49% 
had signs of active uveitis or were receiving topical glucocorticoids for recent flares.  Similar 
persistence into adulthood of asymptomatic uveitis in almost half of patients with JIA-U was 
seen in a cohort of 19 subjects who were born in 1976-1980 (101). 
 
What features predict more severe course and development of complications? 
 The risk factors for poor prognosis in JIA-U include: male gender; young age at onset 
of uveitis; short duration between onset of arthritis and development of uveitis; and presence 
of synechiae at first diagnosis of uveitis (102-104).  A retrospective case series (n = 65) 
showed significantly worse VA in boys versus girls at 1 year and 3 year follow-up (105).  
Another study suggested that a shorter time interval between arthritis and uveitis onset is the 
  
main predictor of severity of uveitis (106).  Risk factors for visual loss, were examined in a 
retrospective study with 596 affected eyes (99).  The overall incidence of visual loss to 20/50 
or worse was 0.18/eye year (EY).  The overall rate of developing a new ocular complication 
was 0.15/EY but significantly lower at 0.04/EY in those with no complications at baseline. 
The same study also showed bilateral uveitis, active uveitis (≥1+ AC cells or ≥ 0.5 vitreous 
haze), longer duration of uveitis, presence of posterior synechiae, abnormal intraocular 
pressure (IOP) and history of prior intraocular surgery were associated with worse vision 
during follow-up. 
 
 
 
 
CONCLUSION AND FUTURE DIRECTIONS 
 
Better understanding of the pathogenesis of JIA-U may help to identify biomarkers, 
either genetic or in plasma, which would allow stratification of patients to higher risk groups.  
These could be targeted with earlier and more aggressive therapy.   
Key to improvement of therapies is the effective translation from bench to bedside 
(107).  High quality evidence for efficacy and safety of novel treatments specifically within a 
JIA-U population is required.   
JIA-U remains a challenge for paediatric rheumatologists and ophthalmologists with 
significant numbers of children still developing sight-threatening complications.  Although 
understanding of the pathogenesis of non-infectious uveitis is growing, studies focussing 
specifically on JIA-U are generally lacking.  Recent evidence-based guidelines have 
highlighted the importance of earlier use of systemic immunosuppression with steroid-
sparing agents in cases of persisting uveitis activity.  We now have increasing treatment 
  
options, with an RCT of adalimumab now completed and clinical trials in progress of other 
biological agents for refractory cases.  The identification of predictive biomarkers to help 
target the widening therapeutic armamentarium will be a key goal for the coming years.   
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